Comparison between Natural and Immunized Anti-GM1 Antibodies Analyzed by Marker Releasing Rate Assay with Liposome.
スポンサーリンク
概要
- 論文の詳細を見る
Naturally occurring rabbit anti-GM1 was compared with immunized induced anti-GM1 antibody in the same individual rabbits by the characterization of immune potency determined by complement-dependent damage to liposomes containing GM1 as antigen. Antigen-antibody reaction was the rate determining step in this assay. The maximum rate was measured by the first derivative conversion monitoring in spectrophotometry and the maximum level of marker released was measured by the conventional method described previously. When the concentration of sera required to get fifty percent of maximum values in each assay were compared, the ratios (rate assay/conventional assay) were 5.7 to 10.0 in natural antibodies and 3.2 to 2.3 in immunized induced antibodies, respectively. Furthermore, the maximum rate of marker release from liposome was not correlated with the maximum level of marker released depended on the sources of antibodies. These results suggest that natural antibody, even the titer was high in conventional liposome assay, has different characteristics compared with the immunized induced antibody.
- 久留米大学医学部 The Kurume Medical Journal 編集部の論文
著者
-
Shichijo Shigeki
Department Of Immunology And Immunotherapy Kurume University School Of Medicine
-
YOKOYAMA MITCHEL
Internal Medicine, Kurume University School of Medicine
-
TSUNOSUE RIKA
Departments of Immunology, Kurume University School of Medicine
-
AYABE MITSUYOSHI
Internal Medicine, Kurume University School of Medicine
-
NAKAO MASANOBU
Internal Medicine, Kurume University School of Medicine
関連論文
- Sequence Analysis of Genes Encoding Rodent Homologues of the Human Tumor-rejection Antigen SART-1
- Expression of Tumor-rejection Antigens in Gynecologic Cancers
- Expression of the SART-1 Antigens in Uterine Cancers
- Expression of MAGE-1 Gene by Esophageal Carcinomas
- Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients
- Identification of Cyclophilin B-derived Peptides Capable of Inducing Histocompatibility Leukocyte Antigen-A2-restricted and Tumor-specific Cytotoxic T Lymphocytes
- A GENE ENCODING SQUAMOUS CELL CARCINOMA ANTIGENS RECOGNIZED BY CYTOTOXIC T LYMPHOCYTE
- Genes Encoding Antigenic Peptides of Human Epithelial Cancers Recognized by Cytotoxic T Lymphocytes
- Detection of MAGE-4 Protein in Sera of Lung Cancer Patients
- Human Tumor Rejection Antigens MAGE1^1
- Induction of MAGE Genes in Lymphoid Cells by the Demethylating Agent 5-Aza-2'-deoxycytidine
- Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanona antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease
- Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2^+ glioma patients
- Elevation of Serum MAGE-4 Protein Levels and Prediction of Hepatocellular Carcinogenesis in Patients with Liver Cirrhosis
- Detection of MAGE-4 Protein in the Sera of Patients with Hepatitis-C Virus-associated Hepatocellular Carcinoma and Liver Cirrhosis
- Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles
- Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients
- Development of a New Diagnostic Tool for Pancreatic Cancer: Simultaneous Measurement of Antibodies against Peptides Recognized by Cytotoxic T Lymphocytes
- Comparison between Natural and Immunized Anti-GM1 Antibodies Analyzed by Marker Releasing Rate Assay with Liposome.